相关临床试验
250
101 进行中
药物批准
13
批准总数
监管机构
2
监管机构数
成立时间
1998
进行中（未招募）
97
38.8%
Available
1
0.4%
已完成
66
26.4%
No Longer Available
2
0.8%
尚未招募
4
1.6%
招募中
40
16.0%
暂停
1
0.4%
终止
35
14.0%
Unknown
1
0.4%
撤回
3
1.2%
- Breakthrough Properties acquired the 270,000-square-foot biomanufacturing facility at 215 Shuksan Way in Everett, Washington, for $78 million from its second life science fund. - The firm simultaneously secured a 21-year lease for the entire campus with an undisclosed global biopharma company to establish a U.S. manufacturing facility. - The site was originally built by Seagen at a cost of roughly $350 million but was never occupied after Pfizer acquired Seagen in 2023 and shut the facility down in 2024. - The transaction reflects Breakthrough's growing focus on U.S. biomanufacturing infrastructure amid over $600 billion in recent onshoring commitments from major pharmaceutical companies.
- Seagen Inc. (Nasdaq: SGEN) remains a closely watched antibody-drug conjugate (ADC) developer, with its oncology pipeline and revenue growth framing investor focus as of August 31, 2026. - The company's revenue base combines product sales and collaboration income, with oncology drug sales trending upward while milestone-driven collaboration contributions fluctuate by quarter. - Investors are watching whether Seagen sustains double-digit product sales growth and narrows operating losses while advancing late-stage ADC candidates toward regulatory milestones. - Intensifying competition in lymphomas and solid tumors, alongside high R&D spending, shapes valuation expectations for the specialized oncology innovator.
- Pfizer named Cecile Guegan, Senior Vice President of Finance for the Global Biopharmaceutical Business, as Interim CFO effective August 16, 2025. - Dave Denton stepped down on August 15 to accept a professional opportunity outside the pharmaceutical industry in consumer goods. - Guegan brings more than two decades of Pfizer experience, including leading the integration of Seagen into Pfizer in 2024. - Pfizer stated Denton's departure was unrelated to financial or operating results or any disagreements on financial, operational, accounting, or reporting policies.
- China's NMPA has approved TIVDAK (tisotumab vedotin) as the first antibody-drug conjugate for previously treated recurrent or metastatic cervical cancer in China. - The approval is supported by the global Phase 3 innovaTV 301 trial, which showed a statistically significant overall survival benefit (HR=0.70, p=0.0038) versus chemotherapy. - The China subpopulation demonstrated a 45% reduction in the risk of death (HR: 0.55), with consistent benefit regardless of prior anti-PD(L)1 therapy exposure. - Approximately 150,000 new cervical cancer cases are diagnosed annually in China, where treatment options remain limited after chemotherapy failure.
- Corrixr Therapeutics appointed Nancy Whiting, PharmD, former Seagen executive, as Chair of the Board of Directors as the company advances toward the clinic. - Whiting brings over 15 years of oncology drug development experience from Seagen, where she contributed to approvals of ADCETRIS, PADCEV, TUKYSA, and TIVDAK. - Corrixr's lead program, CXR101, uses CRISPR-based gene editing delivered via lipid nanoparticles to eliminate the NRF2 transcription factor in squamous cell carcinomas. - The company targets lung, head & neck, and esophageal squamous cell carcinomas, aiming for IND filing and first-in-human proof-of-mechanism trials.
- Frontier Medicines appointed David R. Epstein, former CEO of Seagen and Novartis Pharmaceuticals, to its board of directors to support the company's next phase of growth. - Epstein brings over 30 years of drug development experience and played a central role in developing more than 30 new molecular entities and over 100 approved indications. - The appointment comes as Frontier advances its pipeline of covalent precision medicines, including FMC-242 and FMC-376, targeting previously undruggable proteins in oncology and immunology. - Frontier's proprietary platform integrates chemoproteomics and AI to unlock difficult-to-drug disease-causing proteins, with its Druggability Atlas covering more than 90% of the human proteome.
- Sanofi and Pfizer's CEACAM5-targeting ADC tusamitamab sonditecan has been placed on clinical hold in France, Spain, Sweden, and the Netherlands, though the specific reason remains undisclosed. - The halted ADC uses the same valine-lysine-glycuronide linker and topoisomerase 1 inhibitor payload as Pfizer's discontinued PF-08046044, which was terminated due to increased toxicity. - Despite the setback, Merck KGaA plans to advance its competing CEACAM5 ADC precemtabart tocentecan into phase 3 colorectal cancer trials in Q2/Q3 2026, based on a 27% response rate in heavily pretreated patients. - The development represents continued industry interest in CEACAM5 as a target despite previous failures, including Sanofi's tusamitamab ravtansine which failed phase 3 in lung cancer.
- Revolution Medicines is reportedly in acquisition talks with Merck for up to $32 billion, which would represent the largest biotech deal since Pfizer's $45.6 billion acquisition of Seagen in 2023. - The potential acquisition comes as Merck faces patent expiry for its blockbuster cancer drug Keytruda in 2028, which generated $31.6 billion in sales last year and represents about half of the company's annual revenue. - Global biotech M&A activity has surged to $228.4 billion in announced deals in 2025, up from $132.3 billion in 2024, driven by pharmaceutical giants seeking to replace revenue from drugs losing patent protection. - Revolution Medicines' late-stage oral cancer treatment Daraxonrasib appears to be the key asset driving acquisition interest, with reports suggesting a potential bidding war occurred between multiple pharmaceutical companies.
- A phase II study evaluated tucatinib plus trastuzumab in patients with chemotherapy-refractory, HER2-positive, RAS wild-type colorectal cancer as part of the MOUNTAINEER trial. - The combination therapy demonstrated clinical activity in this heavily pretreated patient population with limited treatment options. - The study represents a significant advance in targeting HER2-positive colorectal cancer, a rare but clinically important subset representing approximately 2-3% of all colorectal cancers. - Results support further investigation of HER2-targeted dual blockade strategies in this challenging patient population.
- Pfizer's PADCEV, acquired through the $43 billion Seagen purchase, demonstrated exceptional Phase 3 results when combined with Merck's KEYTRUDA in muscle-invasive bladder cancer patients ineligible for cisplatin chemotherapy. - The combination therapy significantly reduced disease progression and mortality risk, addressing a critical unmet need for approximately half of muscle-invasive bladder cancer patients who cannot receive standard cisplatin treatment. - Pfizer's oncology revenue grew 11% year-over-year to $4.39 billion, with PADCEV alone contributing a 38% increase, signaling successful execution of the company's strategic pivot to targeted cancer therapies. - The strong clinical performance validates Pfizer's controversial acquisition strategy and demonstrates the potential of antibody-drug conjugate technology to transform cancer treatment outcomes.
